| Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. | |
| | |
MedLine Citation:
|
PMID: 16422827 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Erectile dysfunction (ED) is a highly prevalent, often undertreated condition. AIM: This 12-week, double-blind, parallel, placebo-controlled study was conducted at 25 sites in Canada to evaluate the efficacy and safety of oral tadalafil, a phosphodiesterase type 5 inhibitor, for the treatment of ED. METHODS: Men with ED of organic, psychogenic, or mixed etiology were stratified by baseline ED severity then randomly assigned to placebo (N = 50), tadalafil 10 mg (N = 103), or tadalafil 20 mg (N = 100), taken as needed (maximum, once daily). MAIN OUTCOME MEASURES: Efficacy was assessed by the International Index of Erectile Function (IIEF), a Sexual Encounter Profile diary, and a global assessment question (GAQ). RESULTS: Tadalafil 10 mg and tadalafil 20 mg significantly improved erectile function compared with placebo (P < 0.001, all measures). At end point, the mean IIEF erectile function (EF) domain scores were 14.5, 21.2, and 23.3 of a possible score of 30 for placebo, tadalafil 10 mg, and tadalafil 20 mg, respectively. Patients treated with tadalafil reported greater change from baseline on the IIEF EF domain score compared with placebo, regardless of baseline ED severity. During treatment, the mean per-patient proportion of successful intercourse attempts was higher for tadalafil 10 mg and 20 mg than for placebo (placebo, 31.9%; tadalafil 10 mg, 56.7%; and tadalafil 20 mg, 61.5%), and a greater proportion of patients reported improved erections with tadalafil (GAQ; placebo, 22.0%; tadalafil 10 mg, 67.0%; tadalafil 20 mg, 79.0%). Fifty percent and 62% of patients treated with tadalafil 10 mg and 20 mg, respectively, achieved successful sexual intercourse after their first dose, compared with 31% with placebo. Treatment-emergent adverse events were generally mild or moderate. CONCLUSION: Tadalafil was an effective, well-tolerated therapy for ED of broad-spectrum etiology and severity. |
| | |
Authors:
|
Serge Carrier; Gerald B Brock; Peter J Pommerville; Janey Shin; Greg Anglin; Steven Whitaker; Charles M Beasley |
Related Documents
:
|
18789827 - Erectile dysfunction and depressive mood in men with coronary heart disease. 11701687 - Alendronate treatment of established primary osteoporosis in men: results of a 2-year p... 16469617 - Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction ... 20828247 - Lower urinary tract symptoms and erectile dysfunction associated with depression among ... 19646367 - Somatic versus cognitive symptoms of depression as predictors of all-cause mortality an... 20833937 - Symptom presentation, interventions, and outcome of emotionally-distressed patients in ... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: The journal of sexual medicine Volume: 2 ISSN: 1743-6095 ISO Abbreviation: - Publication Date: 2005 Sep |
Date Detail:
|
Created Date: 2006-01-20 Completed Date: 2006-03-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101230693 Medline TA: J Sex Med Country: United States |
Other Details:
|
Languages: eng Pagination: 685-98 Citation Subset: IM |
Affiliation:
|
Department of Urology, Jewish General Hospital, 3755 Côte Sainte-Catherine E-210, Montreal, Quebec, Canada H3T 1E2. serge.carrier@mcgill.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
3',5'-Cyclic-GMP Phosphodiesterases Administration, Oral Adult Aged Canada Carbolines / administration & dosage, adverse effects*, therapeutic use* Cyclic Nucleotide Phosphodiesterases, Type 5 Double-Blind Method Drug Administration Schedule Erectile Dysfunction / drug therapy*, etiology*, physiopathology Humans Male Middle Aged Phosphoric Diester Hydrolases / metabolism Severity of Illness Index Treatment Outcome Vasodilator Agents / administration & dosage, adverse effects*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Carbolines; 0/Vasodilator Agents; 0/tadalafil; EC 3.1.4.-/Phosphoric Diester Hydrolases; EC 3.1.4.35/3',5'-Cyclic-GMP Phosphodiesterases; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5; EC 3.1.4.35/PDE5A protein, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sexual experience of female partners of men with erectile dysfunction: the female experience of men'...
Next Document: Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, ra...